Escitalopram proves dominant over sertraline in MDD
|
Is it curtains for the blockbuster model?
|
According to the chief US drug regulator, Andrew von Eschenbach, the US government should not interfere
|
'Sunshine' laws bring little light to pharma payments
|
The American Heart Association (AHA) has announced updated guidelines
|
NFID urges increased flu vaccination in those with DM
|
NCCN oncology guidelines updated
|
Trastuzumab reimbursement decisions not equitable
|
Influenza virus vaccine uptake is low among healthcare workers in Victoria, Australia,
|
Atopic dermatitis costs significant for US employers
|
Aspirin has "favourable" cost utility in older women
|
Teenagers presenting for pregnancy termination are "no less responsible about contraceptive use"
|
Rizatriptan, eletriptan most cost-effective oral triptans for migraine?
|
Timely immunisation linked to parental satisfaction
|
Voriconazole best value for invasive aspergillosis in Spain
|
Pregnancy during isotretinoin use "frequent" in Canada
|
Antithrombotics are prescribed to most outpatients with permanent atrial fibrillation (AF), however the use of vitamin K antagonists decreases with age.
|
Nosocomial neonatal candidaemia increases hospital costs
|
Use of atorvastatin increases following PROVE-IT, REVERSAL
|
Many patients with DM missing lipid targets, missing treatment
|
Economics of expanded hepatitis A vaccination "reasonable"
|
UK NHS walk-in centres: no impact on primary care access
|
Clinical prescribing and the secondary prevention of PTSD
|
Hyperlipidaemia frequently undertreated after ED visits for ACS
|
News from CROI
|
The Australian government is to allocate approximately $A70 million* to community pharmacies
|
Cost of medicines rising in Austria
|
Costs of paediatric studies grow
|
Poland: 30% increase in healthcare funding
|
The Russian government has granted approval for a federal programme
|
Japan has announced a new contribution of $US186 million
|
A "full and far reaching" plan has been introduced by the South African government
|
Sanofi-aventis has announced that its cannabinoid 1 receptor antagonist, Acomplia [rimonabant],
|
WHO has issued new guidance calling for the introduction of pneumococcal conjugate vaccines into immunisation programmes for developing countries.
|